192 related articles for article (PubMed ID: 12796575)
1. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.
Woltering EA; Lewis JM; Maxwell PJ; Frey DJ; Wang YZ; Rothermel J; Anthony CT; Balster DA; O'Leary JP; Harrison LH
Ann Surg; 2003 Jun; 237(6):790-8; discussion 798-800. PubMed ID: 12796575
[TBL] [Abstract][Full Text] [Related]
2. Metronomic dosing enhances the anti-angiogenic effect of epothilone B.
Stalder MW; Anthony CT; Woltering EA
J Surg Res; 2011 Aug; 169(2):247-56. PubMed ID: 20338584
[TBL] [Abstract][Full Text] [Related]
3. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Lyons JM; Anthony CT; Thomson JL; Woltering EA
Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
[TBL] [Abstract][Full Text] [Related]
4. A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay.
Gulec SA; Woltering EA
Ann Surg Oncol; 2004 Jan; 11(1):99-104. PubMed ID: 14699041
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate.
Watson JC; Redmann JG; Meyers MO; Alperin-Lea RC; Gebhardt BM; Delcarpio JB; Woltering EA
Surgery; 1997 Aug; 122(2):508-13; discussion 513-4. PubMed ID: 9288159
[TBL] [Abstract][Full Text] [Related]
6. Effect of human recombinant Endostatin protein on human angiogenesis.
Jung SP; Siegrist B; Hornick CA; Wang YZ; Wade MR; Anthony CT; Woltering EA
Angiogenesis; 2002; 5(1-2):111-8. PubMed ID: 12549868
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
8. Effect of human Angiostatin protein on human angiogenesis in vitro.
Jung SP; Siegrist B; Wang YZ; Wade MR; Anthony CT; Hornick C; Woltering EA
Angiogenesis; 2003; 6(3):233-40. PubMed ID: 15041799
[TBL] [Abstract][Full Text] [Related]
9. A study of pipeline drugs in neuroendocrine tumors.
Anthony CT; Bastidas JG; Thomson JL; Lyons J; Lewis JM; Schwimer JE; Casey P; Abadie J; Frey DJ; Wang YZ; Boudreaux JP; Woltering EA
J Gastrointest Cancer; 2012 Jun; 43(2):296-304. PubMed ID: 21556722
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation.
Gulec SA; Gaffga CM; Anthony CT; Su LJ; O'Leary JP; Woltering EA
Am Surg; 2001 Nov; 67(11):1068-71. PubMed ID: 11730223
[TBL] [Abstract][Full Text] [Related]
11. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
12. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
14. A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos.
Vollmer LL; Jiménez M; Camarco DP; Zhu W; Daghestani HN; Balachandran R; Reese CE; Lazo JS; Hukriede NA; Curran DP; Day BW; Vogt A
Mol Cancer Ther; 2011 Jun; 10(6):994-1006. PubMed ID: 21490306
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Antiangiogenic Efficacy of Emilia sonchifolia (L.) DC on Tumor-Specific Neovessel Formation by Regulating MMPs, VEGF, and Proinflammatory Cytokines.
Gilcy GK; Kuttan G
Integr Cancer Ther; 2016 Dec; 15(4):NP1-NP12. PubMed ID: 27146127
[TBL] [Abstract][Full Text] [Related]
16. Approaches to preclinical screening of antiangiogenic agents.
Kruger EA; Duray PH; Price DK; Pluda JM; Figg WD
Semin Oncol; 2001 Dec; 28(6):570-6. PubMed ID: 11740811
[TBL] [Abstract][Full Text] [Related]
17. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Özcetin A; Aigner A; Bakowsky U
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):711-5. PubMed ID: 23891770
[TBL] [Abstract][Full Text] [Related]
18. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
19. The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.
Bellou S; Karali E; Bagli E; Al-Maharik N; Morbidelli L; Ziche M; Adlercreutz H; Murphy C; Fotsis T
Mol Cancer; 2012 May; 11():35. PubMed ID: 22583931
[TBL] [Abstract][Full Text] [Related]
20. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
